About Argenta

Business strategy

Argenta is a reliable contract drug discovery organisation

Argenta has a successful fee-for-service contract research business. We undertake clients' entire discovery programmes or elements thereof, including hit identification, hit-to-lead, and lead optimisation. Argenta works closely with its clients, focusing on integrated project management and open communication. We contribute resource, expertise, and guidance as required, and also provide support for patent and intellectual property issues. Our staff have expertise in a broad range of therapeutic areas and target classes.

Corporate highlights

2000 - Argenta Discovery founded as spin-out of Aventis Pharma UK
2002 - Etiologics founded as spin-out of Bayer Pharmaceuticals UK
2004 - Argenta Discovery and Etiologics merge
2010 - Acquisition of Argenta Discovery 2009 Ltd. by Galapagos

Unparalleled expertise

Argenta’s management and staff have a wealth of pharmaceutical industry experience and a track record of success in pharmaceutical R&D.

Our staff have a combined total of over 1300 scientific publications, and over 950 patents in many therapeutic areas. In addition, they have been responsible for taking over 80 compounds to clinical development, with 25 of these reaching the market.